Markets:

Overview

News

Currencies

International

Treasuries

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

7.250 -2.150 (-22.87%)

Streaming Delayed Price Updated: 1:59 PM EDT, Mar 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ImmunityBio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Why ImmunityBio Stock Is Down More Than 20% Today ↗

Today 12:59 EDT

Perhaps the company's management will be more careful after a third regulatory run-in.

Via The Motley Fool

There are notable gap-ups and gap-downs in today's session. ↗

Today 11:30 EDT

Via Chartmill

ImmunityBio Crashes On FDA Warning Over Anktiva Claims ↗

Today 11:04 EDT

ImmunityBio, Inc. (NASDAQ: IBRX) shares are trading lower after the FDA issued a warning to the company over misleading Anktiva promotions.

Via Benzinga

Why ImmunityBio Stock Is Up More Than 11% Today ↗

March 23, 2026

The young biopharma outfit's growth potential continues to expand.

Via The Motley Fool

ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors

March 20, 2026

From ImmunityBio, Inc.

Via Business Wire

Stocks Under $10: IBRX, VTIX, NDRA, SMX – 2026 Watch Now!

March 19, 2026

Via AB Newswire

Why Did IBRX Stock Jump 7% In Pre-Market Today? ↗

March 17, 2026

The NCCN updated its 2026 bladder cancer guidelines to include ANKTIVA for more patients. This move broadens its potential use, though the indication is still not FDA-approved.

Via Stocktwits

ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA® Plus BCG for Patients With BCG-Unresponsive NMIBC With Papillary-Only Disease

March 17, 2026

From ImmunityBio, Inc.

Via Business Wire

IBRX Stock Rises Overnight: Retail Bets Anktiva’s NCCN 'Recommended' Tag Will Drive Prescriptions And Insurance Wins ↗

March 17, 2026

Users highlighted that NCCN inclusion could lead to increased prescribing of Anktiva by oncologists and improved insurance reimbursement.

Via Stocktwits

Topics ETFs

IBRX Stock Rises 3% Pre-Market: ImmunityBio Reports Breakthrough In NK Cell Therapy Production ↗

March 13, 2026

ImmunityBio also completed a Phase 1 study combining its memory cytokine-enhanced NK cell therapy with ANKTIVA.

Via Stocktwits

ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors

March 13, 2026

From ImmunityBio, Inc.

Via Business Wire

IBRX Stock Down 10% This Week, But Its CEO Just Outlined 3 Reasons Bull Case Is Intact ↗

March 12, 2026

The company expects global expansion to drive “substantial” revenue starting in 2027.

Via Stocktwits

Why 2 Small Biotechs May Hold the Key to New Cancer Treatments ↗

March 12, 2026

Via MarketBeat

IBRX Stock Rout Deepens: Founder Points To Cancer-Fighting Cell Bank Data As Investors Look For Catalyst ↗

March 11, 2026

The project relies on an AI-driven manufacturing robot, Leonardo, to automate production and potentially scale NK cell output.

Via Stocktwits

Topics Artificial Intelligence

IBRX Stock Declines Pre-Market — ImmunityBio Resubmits Anktiva Application To FDA With Additional Data ↗

March 09, 2026

ImmunityBio stated that the application includes additional information requested by the FDA to support its supplemental BLA for papillary disease.

Via Stocktwits

Can IBRX Stock Snap Its 4-Day Slide? Founder Promises ‘Game-Changer’ Anktiva Data As FDA Speeds Drug Reviews ↗

March 09, 2026

The founder cited remarks from a former FDA official and an NIH Director supporting mechanism-based review to speed patient access to therapies like Anktiva.

Via Stocktwits

IBRX Founder’s ‘Congrats’ To GSK Sparks Debate After FDA Fast Drug Approvals — Retail Slams Big Pharma Bias Over Anktiva ↗

March 06, 2026

Investors are focused on Anktiva’s next regulatory step, as ImmunityBio seeks to expand the therapy to BCG-unresponsive papillary bladder cancer.

Via Stocktwits

Forget ImmunityBio: This Big‑Cap Pharma Is the Safer Play on Next‑Gen Cancer Therapies ↗

March 05, 2026

Merck can help stabilize investors' portfolios, whereas ImmunityBio would be a source of volatility.

Via The Motley Fool

IBRX Vs IOVA: Which Cancer Immunotherapy Stock Has Bigger Breakout Ahead? ↗

March 05, 2026

Investors are increasingly comparing ImmunityBio and Iovance Biotherapeutics as both cancer drug developers move into catalyst-heavy phases.

Via Stocktwits

IBRX Stock Drops On Investor Concerns Over Immunotherapy Launch In Saudi Arabia Amid Middle East Tensions But Analyst Sees 20% Upside ↗

March 04, 2026

Piper Sandler raised the firm's price target on ImmunityBio to $12 from $7 and kept an ‘Overweight’ rating on the shares.

Via Stocktwits

Topics Intellectual Property

ImmunityBio (IBRX) Shares Plummet Despite Piper Sandler Price Target Hike and 700% Revenue Growth

March 04, 2026

In a classic case of "selling the news," shares of ImmunityBio, Inc. (NASDAQ: IBRX) took a sharp dive on Wednesday, March 4, 2026, plummeting over 13% to close at $9.02. The sell-off came as a surprise...

Via MarketMinute

Topics Earnings Economy

Dow, S&P 500, Nasdaq Futures Slip As Middle East War Fuels Oil Rally: Why MU, IBRX, BATL, DJT, SE Are On Traders’ Radar Today ↗

March 03, 2026

Investors are looking at earnings from Abercrombie & Fitch, Broadcom and Okta on Wednesday.

Via Stocktwits

Topics ETFs Government Stocks

IBRX Stock Tumbles After-Hours: Flags ‘Terrible’ BCG Shortage As Saudi Anktiva Launch Nears Amid Middle East Tensions ↗

March 03, 2026

To address the BCG shortage, ImmunityBio highlighted its recombinant BCG program, with 580 patients enrolled across about 100 clinical sites.

Via Stocktwits

Topics Earnings Supply Chain

IBRX Stock Extends Rally To Day 3: Founder Drops ‘Prelude’ To 2025 Earnings, Slams Bristol Myers, Amgen Cancer Playbook ↗

March 03, 2026

The founder criticized traditional chemotherapy approaches from Amgen and Bristol Myers and hyped up the mechanism behind Anktiva.

Via Stocktwits

Topics Artificial Intelligence

IBRX Stock Eyes Green Open Ahead Of Earnings — What Happened With Anktiva Over The Weekend ↗

March 02, 2026

Founder Patrick Soon-Shiong spotlighted Anktiva on national TV, emphasizing IL-15’s potential to activate the immune system and its combination approach with Merck’s Keytruda.

Via Stocktwits

Topics Artificial Intelligence

ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026

February 27, 2026

From ImmunityBio

Via Business Wire

IBRX Stock Ignites Retail Frenzy Ahead Of Founder’s Prime-Time TV Blitz — Traders Bets On Saudi Funding And Trump Tailwinds ↗

February 26, 2026

Founder Patrick Soon-Shiong is set for back-to-back prime-time interviews on Fox News and NewsNation on Friday.

Via Stocktwits

Topics Government

IBRX Stock Rises Pre-Market After ANKTIVA Combo Shows Stronger Bladder Cancer Responses In Phase 2 Trial ↗

February 26, 2026

The company said it plans to submit a biologics license application by the fourth quarter of 2026.

Via Stocktwits

ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

February 26, 2026

From ImmunityBio, Inc.

Via Business Wire

Nasdaq, S&P 500 Futures Tread Caution On Nvidia’s China Risk: Why NFLX, WBD, AAPL, CRM, AI, LRMR Are On Traders' Radar Today ↗

February 26, 2026

Data from Stocktwits showed that retail sentiment on SPY and QQQ diverged.

Via Stocktwits

Topics Artificial Intelligence ETFs Stocks

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.